166 related articles for article (PubMed ID: 12713628)
1. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
Sington JD; Morris LS; Nicholson AG; Coleman N
Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
[TBL] [Abstract][Full Text] [Related]
2. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
3. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
Cagle PT; Churg A
Arch Pathol Lab Med; 2005 Nov; 129(11):1421-7. PubMed ID: 16253023
[TBL] [Abstract][Full Text] [Related]
4. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations.
Taheri ZM; Mehrafza M; Mohammadi F; Khoddami M; Bahadori M; Masjedi MR
Arch Pathol Lab Med; 2008 Apr; 132(4):694-7. PubMed ID: 18384222
[TBL] [Abstract][Full Text] [Related]
6. Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
Nind NR; Attanoos RL; Gibbs AR
Histopathology; 2003 Feb; 42(2):150-5. PubMed ID: 12558747
[TBL] [Abstract][Full Text] [Related]
7. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
[TBL] [Abstract][Full Text] [Related]
8. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
[TBL] [Abstract][Full Text] [Related]
9. β-catenin expression in benign and malignant pleural disorders.
Anani W; Bruggeman R; Zander DS
Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
[TBL] [Abstract][Full Text] [Related]
10. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
11. Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?
Kimura F; Kawamura J; Watanabe J; Kamoshida S; Kawai K; Okayasu I; Kuwao S
Diagn Cytopathol; 2010 Mar; 38(3):161-7. PubMed ID: 19821496
[TBL] [Abstract][Full Text] [Related]
12. [Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].
Krismann M; Thattamparambil P; Simon F; Johnen G
Pathologe; 2006 Mar; 27(2):99-105. PubMed ID: 16435096
[TBL] [Abstract][Full Text] [Related]
13. [Observation of the morphological genesis of pleural mesothelioma induced by asbestos in rats].
Wang C; Luo S; Liu X
Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):181-4. PubMed ID: 1452154
[TBL] [Abstract][Full Text] [Related]
14. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
[TBL] [Abstract][Full Text] [Related]
15. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
16. Computerized interactive morphometry. A study of malignant mesothelioma and mesothelial hyperplasia in pleural biopsy specimens.
Marchevsky AM; Gil J; Caccamo D
Arch Pathol Lab Med; 1985 Dec; 109(12):1102-5. PubMed ID: 3840984
[TBL] [Abstract][Full Text] [Related]
17. [Expression of glucose transporter protein 1 and desmin in reactive mesothelial hyperplasia and epithelioid malignant mesothelioma].
Wei P; Jin ML; Zhao HY; Li X; Diao XL
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):451-4. PubMed ID: 24246863
[TBL] [Abstract][Full Text] [Related]
18. My approach to the diagnosis of mesothelial lesions.
Butnor KJ
J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.
Kortsik CS; Werner P; Freudenberg N; Virchow JC; Kroegel C; Pott M; Matthys H
Lung; 1995; 173(2):79-87. PubMed ID: 7536281
[TBL] [Abstract][Full Text] [Related]
20. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
